# US Salivary Gland Infection Market > US Salivary Gland Infection Market Research Report By Diagnosis (Plain radiography, sialography, high-resolution ultrasonography, Computed tomography (CT), Magnetic Resonance Imaging (MRI), radionuclide scintigraphy, others, CT sialography (ultrafast technique), fluoroscopic/conventional sialography (with or without digital subtraction), MR sialography), By Treatment (medication, surgery, aspiration, home care, others, antibiotics, dicloxacillin, cephalosporins, clindamycin, others, removal of part of the parotid salivary gland, removal of all of the parotid salivary gland, removal of the submandibular salivary gland, others, increased water intake, rest, refraining from smoking, massaging the gland with heat, others) and By End User (hospitals & clinics, medical research centers, academic institutes, others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.19% - **2024:** $ 171.2 Million - **2025:** $ 181.8 Million - **2035:** $ 331.5 Million - **Key Players:** GlaxoSmithKline (GB), Merck & Co (US), AbbVie (US), Bristol-Myers Squibb (US), AstraZeneca (GB), Novartis (CH), Sanofi (FR), Johnson & Johnson (US) **Report ID:** MRFR/Pharma/17473-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-salivary-gland-infection-market-19019 --- ## Market Summary ## **US Salivary Gland Infection Market Overview** As per MRFR analysis, the US Salivary Gland Infection Market Size was estimated at 1.21 (USD Billion) in 2023. The US Salivary Gland Infection Market Industry is expected to grow from 1.5 (USD Billion) in 2024 to 4 (USD Billion) by 2035. The US Salivary Gland Infection Market CAGR (growth rate) is expected to be around 9.326% during the forecast period (2025 - 2035). ### **Key Market Trends Highlighted** The US Salivary Gland Infection Market is experiencing several key trends shaped by advancements in medical practices and rising awareness among the public. One significant market driver is the increasing prevalence of salivary gland infections, often linked to viral infections, dehydration, and autoimmune diseases. With the aging population in the US, the demand for effective treatment options has risen. Innovative diagnostic tools, such as salivary diagnostic tests, are being developed, which enhance the ability to detect infections early, leading to better patient outcomes. There are also opportunities to be explored in the development of new therapies and treatment methods targeting the underlying causes of salivary gland infections. Increased investment in research and development by pharmaceutical and biotechnology companies, along with support from the US government, provides a promising environment for creating novel interventions. Healthcare providers are increasingly focusing on tailored solutions, such as personalized medicine and minimally invasive procedures, to address the needs of patients affected by these infections. Recent trends show a notable rise in public health campaigns aimed at educating individuals about the importance of oral hygiene and hydration in preventing salivary gland infections. This growing awareness may lead to increased screening and early intervention, which can help mitigate the severity of infections. Additionally, telemedicine is becoming more prevalent, allowing patients to consult healthcare professionals conveniently, thereby improving access to care. All these dynamics indicate that the US Salivary Gland Infection Market is poised for growth as stakeholders respond to emerging healthcare needs and demographic shifts. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **US Salivary Gland Infection Market Drivers** ### **Increasing Prevalence of Salivary Gland Infections** The US Salivary Gland Infection Market Industry is witnessing significant growth due to the rising prevalence of salivary gland infections, particularly sialadenitis and sialolithiasis. According to the National Institute of Dental and Craniofacial Research (NIDCR), approximately 10% of adults in the United States will experience a salivary gland disorder in their lifetime. The increasing incidence of mumps, a viral infection that primarily affects the salivary glands, also contributes to this trend. The Centers for Disease Control and Prevention (CDC) reported a notable increase in mumps cases in the US, indicating a need for better treatment options and management strategies, thereby driving the market for salivary gland infection therapies. This underscores the growing demand for effective and advanced therapeutic solutions in the US Salivary Gland Infection Market, addressing the healthcare needs of a substantial population. ### **Advancements in Medical Technology** Innovations in medical technology play a crucial role in the growth of the US Salivary Gland Infection Market Industry. Enhanced imaging techniques, such as ultrasound and Magnetic Resonance Imaging (MRI), improve the diagnosis of salivary gland infections, leading to timely and effective treatments. The American College of Radiology emphasizes the importance of advanced imaging in accurately diagnosing salivary gland disorders. Furthermore, the introduction of minimally invasive surgical techniques and novel treatment modalities, including the use of lasers and endoscopic approaches, have revolutionized patient care. These advancements not only enhance treatment outcomes but also reduce recovery times, thereby increasing patient satisfaction and contributing to a thriving market. ### **Growing Awareness and Education on Oral Health** There is a surge in awareness and education regarding oral health in the US, propelling the growth of the US Salivary Gland Infection Market Industry. Organizations like the American Dental Association (ADA) are intensifying efforts to educate the public about the importance of salivary gland health and associated diseases. Increased access to information and community outreach programs have led to a more informed public regarding the symptoms and risks linked to salivary gland infections. This heightened awareness encourages individuals to seek medical attention promptly, resulting in early diagnosis and treatment. The emphasis on preventive measures, including regular dental check-ups, is expected to foster growth in the salivary gland infection market as more individuals become proactive in managing their oral health. ## **US Salivary Gland Infection Market Segment Insights** ### **Salivary Gland Infection Market Diagnosis Insights** The Diagnosis segment of the US Salivary Gland Infection Market plays a crucial role in the identification and management of salivary gland disorders. This segment encompasses various advanced imaging techniques that facilitate the accurate diagnosis of conditions affecting the salivary glands. Techniques such as plain radiography are fundamental for initial assessments and can provide preliminary information about the anatomy and structure of salivary glands. Sialography, on the other hand, allows for detailed visualization of the salivary duct system, making it invaluable for diagnosing obstructions, strictures, or stones. High-resolution ultrasonography offers a non-invasive alternative with the added advantage of providing real-time imaging, enabling the detection of lesions or inflammation effectively.  Computed tomography (CT) and Magnetic Resonance Imaging (MRI) are significant modalities that enhance diagnostic accuracy for complex cases by providing high-quality images that aid in evaluating salivary gland pathologies. CT scans are particularly efficient in assessing various anatomical structures in detail, while MRI excels in soft tissue characterization, making both techniques indispensable in the diagnosis process. Radionuclide scintigraphy is another valuable tool that measures the function of salivary glands, allowing practitioners to assess salivary production which is critical for comprehensive evaluations. Furthermore, specialized techniques such as CT sialography (ultrafast technique) and MR sialography extensively contribute to the diagnosis by enabling the visualization of the ductal system without the need for contrast medium, making them preferable in specific clinical scenarios.  The fluoroscopic or conventional sialography, whether with or without digital subtraction, has been a long-standing method in salivary gland diagnostics, enabling the identification of strictures or calculi within the ducts. Overall, the diverse methodologies within this Diagnosis segment reflect the rapid advancements in technology and imaging capabilities, aligned with the growing awareness of salivary gland disorders in the US healthcare setting. The rising prevalence of these infections and related disorders reinforces the demand for a comprehensive and effective diagnostic approach, driving innovation and enhancing patient outcomes in the US Salivary Gland Infection Market.  As technology progresses, the integration of artificial intelligence and machine learning could further refine these diagnostic techniques, providing opportunities for early detection and personalized treatment plans that cater to the unique needs of patients with salivary gland infections. Additionally, the growing emphasis on preventive healthcare in the United States underlines the vital significance of accurate and timely diagnosis in managing these conditions effectively, leading to better disease management and an improvement in patients' quality of life. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Salivary Gland Infection Market Treatment Insights** The Treatment segment of the US Salivary Gland Infection Market plays a crucial role in addressing this health concern, which impacts a significant number of individuals across the nation. Various approaches within this segment are utilized, including medication options like antibiotics such as dicloxacillin, cephalosporins, and clindamycin that are essential for combating bacterial infections. Surgical interventions, specifically the removal of part or all of the parotid salivary gland, as well as the removal of the submandibular salivary gland, are pivotal for resolving severe conditions when conservative treatments fail.  Aspiration techniques are also employed to relieve discomfort by draining accumulated fluid. Home care practices, such as increased water intake, resting, refraining from smoking, and massaging the gland with heat, are significant for enhancing recovery and patient comfort. This diverse range of treatments addresses both immediate symptoms and long-term health outcomes, driving the demand for effective solutions within the US. With rising awareness and advancements in treatment options, the segment is well-positioned to support the growing US Salivary Gland Infection Market revenue while meeting patient needs effectively. The segment's evolution reflects ongoing trends toward personalized medicine and an emphasis on patient-centric care strategies. ### **Salivary Gland Infection Market End User Insights** The US Salivary Gland Infection Market showcases a diverse segmentation based on End Users, including hospitals and clinics, medical research centers, academic institutes, and others. Hospitals and clinics play a crucial role in the diagnosis and treatment of salivary gland infections, being the primary point of care for patients experiencing symptoms. Medical research centers contribute significantly to advancements in understanding these infections through innovative studies and clinical trials, thereby fostering improved treatment options.  Academic institutes are essential for educating healthcare professionals about the latest research and treatment methodologies. The other segment covers various healthcare settings that also contribute to patient care and research, underscoring the collaborative nature of the industry. The increasing incidence of salivary gland infections and advancements in medical technologies drives the demand across these segments, ensuring that they remain integral to the market's evolution. Furthermore, government initiatives to promote health awareness can enhance patient visits to both hospitals and clinics, thereby influencing growth trends in the US Salivary Gland Infection Market revenue. ## **US Salivary Gland Infection Market Key Players and Competitive Insights** The US Salivary Gland Infection Market presents a dynamic landscape characterized by the presence of a diverse range of pharmaceutical companies competing to address the needs of patients suffering from salivary gland infections. With increasing awareness regarding oral health and related complications, the market has seen a rise in demand for effective treatment options. This has led to significant advancements in research and development, as companies strive to innovate and enhance their product offerings. The competitive landscape is shaped by various factors including technological advancements, shifting consumer preferences, and regulatory changes, all of which contribute to a challenging yet promising environment for market players. Strategic partnerships and collaborations are also common practices among firms aiming to fortify their market position and broaden their product portfolios. ### **Key Companies** ### **Company Profiles** #### **Merck and Co** Merck and Co has established a strong presence in the US Salivary Gland Infection Market through its robust product offerings and commitment to innovation. The company has been successful in developing effective treatments that cater to the diverse needs of patients with salivary gland infections. Merck’s strengths lie in its extensive research capabilities and a well-established distribution network that allows its products to reach a wide audience. Furthermore, the company's emphasis on quality and safety has earned it a reputation as a trusted player within the healthcare sector. The ongoing efforts in clinical trials and the development of new therapies continue to position Merck and Co as a key competitor, enabling it to effectively respond to evolving market demands and enhance patient outcomes. #### **Teva Pharmaceutical Industries** Teva Pharmaceutical Industries has also made significant strides in the US Salivary Gland Infection Market with a focus on delivering affordable and accessible treatment options. The company’s portfolio includes a variety of generic and specialty medications specifically aimed at effectively managing salivary gland infections. Teva's market presence is bolstered by its strong distribution capabilities and strategic collaborations that augment its reach within the US healthcare system.  The strengths of Teva lie in its ability to respond quickly to market trends, ensuring a steady supply of essential medications. Recent mergers and acquisitions have further strengthened the company’s position, enabling it to diversify its product offerings and enhance its research and development capabilities. Teva's commitment to providing innovative solutions tailored to the needs of healthcare providers and patients underpins its strategy in the competitive environment of the US Salivary Gland Infection Market. ## **US Salivary Gland Infection Market Industry Developments** The US Salivary Gland Infection Market has witnessed several notable developments recently. In October 2023, Gilead Sciences announced the initiation of a new clinical study focused on innovative antiviral therapies for treating salivary gland infections, emphasizing their commitment to tackling unmet medical needs in this area. Additionally, Merck and Co. reported a significant milestone in their Research and Development efforts for a new antibiotic designed to combat bacterial infections related to the salivary glands. Over the last couple of years, several companies, including Teva Pharmaceutical Industries and AstraZeneca, have increased their investments in developing combined therapies, which are expected to enhance treatment outcomes.  In the realm of mergers and acquisitions, Novartis completed its acquisition of a biopharmaceutical firm in September 2023, which is expected to bolster its product pipeline for infections, including those affecting salivary glands. These movements indicate a robust interest and growth in the market, driven by both innovative R&D and strategic business expansions by leading companies such as Bristol Myers Squibb and Eli Lilly, enhancing their capabilities in addressing salivary gland infections effectively. ## **US Salivary Gland Infection Market Segmentation Insights** ### **Salivary Gland Infection Market Diagnosis Outlook** ### **Salivary Gland Infection Market Treatment Outlook** ### **Salivary Gland Infection Market End User Outlook** ## Market Drivers ### Growing Geriatric Population The aging population in the US is a critical driver for the salivary gland-infection market. Older adults are more susceptible to various health issues, including salivary gland infections, due to factors such as decreased immune function and the presence of comorbidities. As the geriatric demographic continues to expand, the demand for effective management of salivary gland infections is likely to increase. This trend is underscored by projections indicating that by 2030, nearly 20% of the US population will be aged 65 and older. Consequently, healthcare systems may need to adapt to accommodate the specific needs of this population, leading to an increase in the development and availability of treatments for salivary gland infections. The salivary gland-infection market could see substantial growth as healthcare providers focus on addressing the unique challenges faced by older patients. ### Increased Awareness and Education There is a growing awareness regarding salivary gland infections among both healthcare professionals and the general public. Educational initiatives aimed at informing individuals about the symptoms and risks associated with these infections are becoming more prevalent. This heightened awareness is likely to lead to earlier diagnosis and treatment, which could positively impact the salivary gland-infection market. As patients become more informed, they are more likely to seek medical attention for symptoms that may have previously gone unreported. Furthermore, healthcare providers are increasingly incorporating discussions about salivary gland health into routine check-ups, which may lead to a rise in consultations and subsequent treatments. This trend suggests that the salivary gland-infection market could experience growth as more individuals recognize the importance of oral health and its connection to overall well-being. ### Technological Innovations in Treatment Technological advancements in treatment modalities are significantly influencing the salivary gland-infection market. Innovations such as minimally invasive surgical techniques and the development of targeted therapies are enhancing treatment outcomes for patients. For instance, the introduction of endoscopic procedures allows for more precise interventions with reduced recovery times. Additionally, the emergence of novel pharmacological agents that target specific pathogens associated with salivary gland infections is likely to improve patient outcomes. The market for these advanced treatment options is projected to grow, as healthcare providers increasingly adopt these technologies to enhance patient care. Furthermore, the integration of artificial intelligence in diagnostic processes may streamline the identification of infections, thereby facilitating timely treatment and potentially expanding the salivary gland-infection market. ### Regulatory Support for Innovative Therapies Regulatory bodies in the US are increasingly supportive of the development of innovative therapies for salivary gland infections. Initiatives aimed at expediting the approval process for new treatments are likely to encourage pharmaceutical companies to invest in research and development. This regulatory environment fosters innovation, which could lead to the introduction of novel therapies that address unmet medical needs in the salivary gland-infection market. Additionally, the potential for fast-track designations and priority review vouchers may incentivize companies to focus on this area. As a result, the salivary gland-infection market may experience an influx of new products, enhancing treatment options for patients and potentially improving health outcomes. ### Rising Incidence of Salivary Gland Infections The increasing prevalence of salivary gland infections in the US is a notable driver for the salivary gland-infection market. Factors such as poor oral hygiene, dehydration, and certain medical conditions contribute to this rise. Recent studies indicate that approximately 10% of the population may experience some form of salivary gland infection during their lifetime. This growing incidence necessitates enhanced diagnostic and treatment options, thereby propelling market growth. As healthcare providers become more aware of these infections, the demand for effective therapies and interventions is likely to increase. Consequently, pharmaceutical companies are focusing on developing innovative treatments, which could further stimulate the salivary gland-infection market. The need for effective management strategies is becoming increasingly critical as the population ages and the prevalence of chronic diseases rises. ## Future Outlook The [Salivary Gland Infection Market](https://www.marketresearchfuture.com/reports/salivary-gland-infection-market-3779) is projected to grow at a 6.19% CAGR from 2025 to 2035, driven by advancements in diagnostics, increasing prevalence, and enhanced treatment options. **New opportunities:** - Development of targeted antimicrobial therapies for resistant infections. - Expansion of telehealth services for remote consultations and follow-ups. - Investment in AI-driven diagnostic tools for early detection and treatment planning. By 2035, the market is expected to achieve robust growth, positioning itself as a leader in innovative healthcare solutions. ## Segment Insights ### By Diagnosis: High-resolution ultrasonography (Largest) vs. Computed tomography (CT) (Fastest-Growing) In the US salivary gland-infection market, high-resolution ultrasonography accounts for the largest share of the diagnosis segment, predominantly due to its non-invasive nature and cost-effectiveness. It is widely preferred for its ability to provide real-time imaging of the salivary glands, making it a go-to option among healthcare providers. Computed tomography (CT) follows, providing detailed cross-sectional images that are highly valuable for detecting complex pathologies. The growth trends in the diagnosis segment are significant, particularly for computed tomography (CT), which is emerging as the fastest-growing diagnostic tool. This growth is driven by advancements in imaging technology and increasing instances of salivary gland infections that necessitate precise diagnosis. Additionally, awareness among healthcare professionals regarding the benefits of early detection drives the continuous adoption of these diagnostic modalities, ensuring their prominence in clinical settings. High-resolution ultrasonography (Dominant) vs. Computed tomography (CT) (Emerging) High-resolution ultrasonography stands out as the dominant imaging technique in the US salivary gland-infection market due to its ability to deliver quick and clear images of the salivary glands, allowing for efficient diagnosis and management of infections. Its safety profile, as it employs no ionizing radiation, enhances its appeal among patients and physicians alike. On the other hand, computed tomography (CT) is witnessing rapid adoption and is categorized as an emerging technology in this segment. Offering superior detail and the ability to visualize complex anatomical structures, CT scans are particularly beneficial for diagnosing severe cases, thus capturing the interest of clinicians looking for comprehensive diagnostic options. This combination of high-resolution ultrasonography's established dominance and the growing reliance on CT illustrates the dynamic nature of the diagnosis landscape in the market. ### By Treatment: Medication (Largest) vs. Surgery (Fastest-Growing) In the US salivary gland-infection market, the treatment segment is characterized by a diverse range of approaches including medication, surgery, aspiration, home care, and others. Medication holds the largest share, dominating the market due to its accessibility and effectiveness in managing various salivary gland infections. Surgery, while a smaller segment, is gaining traction as patients seek solutions for persistent or severe conditions, thus reshaping the market landscape. Recent trends indicate a growing preference for more invasive treatments such as surgery. This shift is driven by advancements in surgical technologies and techniques, which enhance patient outcomes and lower recovery times. Additionally, the rise in awareness and diagnosis of salivary gland infections has contributed to greater utilization of both medication and surgical options, as healthcare providers increasingly recognize the importance of timely and effective treatment strategies. Medication (Dominant) vs. Surgery (Emerging) Medication remains the dominant treatment option in the US salivary gland-infection market, appealing to a broad range of patients with mild to moderate symptoms. It includes antibiotics and anti-inflammatory drugs that are often the first line of defense against infections. On the other hand, surgery is emerging as a critical solution for patients with severe cases who require intervention to prevent complications. The surgical approach, though less frequently used, is recognized for its effectiveness and is gradually becoming a preferred option as patient education progresses. Overall, the market is witnessing a balance between the widespread adoption of medication and the selective growth of surgical interventions. ### By End User: Hospitals & Clinics (Largest) vs. Medical Research Centers (Fastest-Growing) In the US salivary gland-infection market, the distribution of market share among the various end-user segments reveals that Hospitals & Clinics represent the largest share, providing extensive services and treatments for patients with salivary gland conditions. This segment effectively utilizes advanced diagnostic tools and treatment technologies, ensuring high operational capacities and patient throughput. In contrast, Medical Research Centers, while smaller in overall share, are growing rapidly, driven by increasing research funding and rising clinical trials aimed at improving therapies for salivary gland infections. The growth trends in this segment are significantly influenced by the increasing number of patients seeking treatment in Hospitals & Clinics due to a growing awareness of salivary gland infections. Furthermore, advancements in medical technology have enabled these facilities to offer improved diagnostic and therapeutic options, boosting patient confidence. However, Medical Research Centers are gaining traction through collaborations with pharmaceutical companies and higher investments in innovations, thus positioning themselves as crucial players in the development of new treatment methodologies. Hospitals & Clinics (Dominant) vs. Medical Research Centers (Emerging) Hospitals & Clinics serve as the dominant segment within the US salivary gland-infection market, equipped with specialized staff and comprehensive treatment protocols that cater to a wide array of patients. They are integral in providing immediate care, advanced diagnostic capabilities, and follow-up treatments, making them the go-to option for patients. Meanwhile, Medical Research Centers, labeled as emerging, focus on pioneering research initiatives and clinical trials aimed at enhancing therapeutic outcomes for salivary gland infections. These centers often collaborate with academic institutions, fostering innovation and breakthrough treatments. Together, both segments play complementary roles, with Hospitals & Clinics addressing immediate patient needs while Medical Research Centers push the boundaries of treatment efficacy and scientific understanding. ## Competitive Benchmarking The salivary gland-infection market is currently characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include an increasing prevalence of salivary gland disorders, heightened awareness of oral health, and advancements in treatment modalities. Major players such as Merck & Co (US), AbbVie (US), and Johnson & Johnson (US) are strategically positioned to leverage these trends. Merck & Co (US) focuses on innovation through research and development, particularly in the realm of biologics, while AbbVie (US) emphasizes strategic partnerships to enhance its product pipeline. Johnson & Johnson (US) is actively pursuing digital transformation initiatives to improve patient engagement and treatment adherence, collectively shaping a competitive environment that is increasingly reliant on technological advancements.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. The collective influence of these key players is significant, as they not only drive innovation but also set industry standards that smaller companies often follow. In October Merck & Co (US) announced a collaboration with a leading biotech firm to develop a novel therapeutic approach for chronic salivary gland infections. This strategic move is likely to enhance Merck's portfolio and position it as a leader in innovative treatment options, reflecting a broader trend towards collaboration in the industry. Such partnerships may facilitate faster development timelines and improved patient outcomes, thereby strengthening Merck's competitive edge. In September AbbVie (US) launched a new digital platform aimed at improving patient access to treatment for salivary gland infections. This initiative underscores AbbVie's commitment to enhancing patient experience and engagement, which is increasingly vital in today's healthcare landscape. By integrating technology into its service offerings, AbbVie is not only addressing patient needs but also differentiating itself from competitors who may not yet fully embrace digital solutions. In August Johnson & Johnson (US) expanded its product line to include a new formulation specifically targeting pediatric patients with salivary gland infections. This strategic expansion reflects an understanding of market needs and the importance of addressing diverse patient demographics. By catering to a younger audience, Johnson & Johnson is likely to capture a significant share of the market, further solidifying its position as a leader in the field. As of November current competitive trends indicate a strong shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may redefine market dynamics, compelling companies to invest in cutting-edge solutions that enhance patient care and operational efficiency. ## Recent News & Developments The US Salivary Gland Infection Market has witnessed several notable developments recently. In October 2023, Gilead Sciences announced the initiation of a new clinical study focused on innovative antiviral therapies for treating salivary gland infections, emphasizing their commitment to tackling unmet medical needs in this area. Additionally, Merck and Co. reported a significant milestone in their Research and Development efforts for a new antibiotic designed to combat bacterial infections related to the salivary glands. Over the last couple of years, several companies, including Teva Pharmaceutical Industries and AstraZeneca, have increased their investments in developing combined therapies, which are expected to enhance treatment outcomes.  In the realm of mergers and acquisitions, Novartis completed its acquisition of a biopharmaceutical firm in September 2023, which is expected to bolster its product pipeline for infections, including those affecting salivary glands. These movements indicate a robust interest and growth in the market, driven by both innovative R&D and strategic business expansions by leading companies such as Bristol Myers Squibb and Eli Lilly, enhancing their capabilities in addressing salivary gland infections effectively. ## Report Scope | MARKET SIZE 2024 | 171.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 181.8(USD Million) | | MARKET SIZE 2035 | 331.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.19% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | GlaxoSmithKline (GB), Merck & Co (US), AbbVie (US), Bristol-Myers Squibb (US), AstraZeneca (GB), Novartis (CH), Sanofi (FR), Johnson & Johnson (US) | | Segments Covered | Diagnosis, Treatment, End User | | Key Market Opportunities | Advancements in diagnostic technologies enhance early detection and treatment options in the salivary gland-infection market. | | Key Market Dynamics | Rising demand for innovative treatments drives competition and regulatory scrutiny in the salivary gland-infection market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US salivary gland-infection market as of 2024?** A: The market valuation was $171.2 Million in 2024. **Q: What is the projected market valuation for the US salivary gland-infection market in 2035?** A: The projected valuation for 2035 is $331.5 Million. **Q: What is the expected CAGR for the US salivary gland-infection market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.19%. **Q: Which companies are the key players in the US salivary gland-infection market?** A: Key players include GlaxoSmithKline, Merck & Co, AbbVie, Bristol-Myers Squibb, AstraZeneca, Novartis, Sanofi, and Johnson & Johnson. **Q: What are the main diagnostic segments in the US salivary gland-infection market?** A: Main diagnostic segments include Plain radiography, Sialography, High-resolution ultrasonography, CT, MRI, Radionuclide scintigraphy, and Others. **Q: What was the revenue range for High-resolution ultrasonography in the US salivary gland-infection market?** A: The revenue range for High-resolution ultrasonography was $30.0 Million to $60.0 Million. **Q: What treatment options are available in the US salivary gland-infection market?** A: Treatment options include Medication, Surgery, Aspiration, Home care, and Others. **Q: What was the revenue range for Surgery in the US salivary gland-infection market?** A: The revenue range for Surgery was $51.84 Million to $100.25 Million. **Q: Which end users are involved in the US salivary gland-infection market?** A: End users include Hospitals & Clinics, Medical Research Centers, Academic Institutes, and Others. **Q: What was the revenue range for Hospitals & Clinics in the US salivary gland-infection market?** A: The revenue range for Hospitals & Clinics was $85.0 Million to $165.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-salivary-gland-infection-market-19019*